BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Cartier Extends Mineralized System 4 km East of Main; Cuts 23.2 g/t Au over 1.0 m at Nordeau ; Expands High-Grade Gold Near Surface at East Nordeau Zone
NevGold Drills 8.51 g/t Oxide AuEq Over 10.6 Meters Within 2.32 g/t Oxide AuEq Over 86.8 Meters ; Discovers High-Grade Oxide Gold-Antimony "Armory Fault" Structure At Bullet Zone
